133 related articles for article (PubMed ID: 1438438)
1. Effects of mafosfamide on the clonogenic cells in precursor B acute lymphoblastic leukemia: significance for ex vivo purging of bone marrow.
Kramer B; Makrynikola V; Bradstock K
Prog Clin Biol Res; 1992; 377():41-7. PubMed ID: 1438438
[No Abstract] [Full Text] [Related]
2. Effect of mafosfamide (ASTA-Z-7654) on the clonogenic cells in precursor-B acute lymphoblastic leukaemia: significance for ex vivo purging of bone marrow for autologous transplantation.
Makrynikola V; Kabral A; Bradstock KF
Bone Marrow Transplant; 1991 Nov; 8(5):351-5. PubMed ID: 1768969
[TBL] [Abstract][Full Text] [Related]
3. Effect of Ethiofos on cytotoxicity of pharmacological purging protocols used for autologous marrow grafts in acute lymphoblastic leukemia.
Skala JP; Rogers PC; Chan KW; Rodriguez WC
Prog Clin Biol Res; 1992; 377():57-62. PubMed ID: 1332075
[No Abstract] [Full Text] [Related]
4. Effect of recombinant human stem cell factor on mafosfamide-treated bone marrow clonogenic cells.
Carlo-Stella C; Mangoni L; Almici C; Caramatti C; Rizzoli V
Stem Cells; 1993 Jul; 11 Suppl 2():170-4. PubMed ID: 7691323
[TBL] [Abstract][Full Text] [Related]
5. The effect of a combined purging with mafosfamide and hyperthermia on murine haemopoietic stem cells and leukaemogenic cells.
Gidáli J; Fehér I
Bone Marrow Transplant; 1992 Dec; 10(6):479-83. PubMed ID: 1490197
[TBL] [Abstract][Full Text] [Related]
6. In vitro effects of Ilmofosine on acute lymphoblastic leukemia cells and on normal hemopoietic cells.
Skala JP; Rogers PC; Chan KW; Khangura SS; Rodriguez WC
Prog Clin Biol Res; 1992; 377():63-9. PubMed ID: 1438445
[No Abstract] [Full Text] [Related]
7. Autologous BMT in high risk patients with CALLA-positive ALL: possible efficacy of ex vivo marrow leukemia cell purging with monoclonal antibodies and complement.
Morishima Y; Miyamura K; Kojima S; Ueda R; Morishita Y; Sao H; Tanimoto M; Ohno R; Sobue R; Hirano M
Bone Marrow Transplant; 1993 Apr; 11(4):255-9. PubMed ID: 7683550
[TBL] [Abstract][Full Text] [Related]
8. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
Carlo-Stella C; Mangoni L; Almici C; Garau D; Craviotto L; Piovani G; Caramatti C; Rizzoli V
Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448
[TBL] [Abstract][Full Text] [Related]
9. Purging with 4-hydroperoxycyclophosphamide combinations.
Jones RJ; Miller CB; Rowley SD
Prog Clin Biol Res; 1992; 377():1-9; discussion 10-1. PubMed ID: 1438406
[No Abstract] [Full Text] [Related]
10. Evaluation of the protection of murine bone marrow stem cells by WR-2721 during in vitro treatment with mafosfamide.
Jiang R; Bony V; Lopez M
Prog Clin Biol Res; 1994; 389():23-9. PubMed ID: 7700906
[No Abstract] [Full Text] [Related]
11. Efficacy of purging clonogenic leukemia cells using ether lipid and hyperthermia for autologous bone marrow transplantation.
Min WS; Park HM; Han CH; Park JW; Kim CC; Kim DJ
Prog Clin Biol Res; 1992; 377():87-95. PubMed ID: 1438449
[No Abstract] [Full Text] [Related]
12. In vitro marrow purging in chronic myelogenous leukemia: effect of mafosfamide and recombinant granulocyte--macrophage colony-stimulating factor.
Carlo-Stella C; Mangoni L; Piovani G; Almici C; Garau D; Caramatti C; Rizzoli V
Bone Marrow Transplant; 1991 Oct; 8(4):265-73. PubMed ID: 1756324
[TBL] [Abstract][Full Text] [Related]
13. Purging of acute lymphoblastic leukemia by long-term marrow culture.
Douay L; Ozsahin H; Barbu V; Fabrega S; Giarratana MC; Da WM; Allieri A; Gorin NC
Prog Clin Biol Res; 1992; 377():205-13; discussion 214. PubMed ID: 1438417
[No Abstract] [Full Text] [Related]
14. Bone marrow purging with antisense oligodeoxynucleotides.
Gewirtz AM
Prog Clin Biol Res; 1992; 377():215-24; discussion 225-6. PubMed ID: 1438418
[No Abstract] [Full Text] [Related]
15. Plasma interacts with mafosfamide toxicity to normal haematopoietic progenitor cells: impact on in vitro marrow purging.
Giarratana MC; Gorin NC; Douay L
Nouv Rev Fr Hematol (1978); 1995; 37(2):125-30. PubMed ID: 7644349
[TBL] [Abstract][Full Text] [Related]
16. Comparative heat sensitivity of murine and human hemopoietic progenitors and clonogenic leukemia cells.
Gidáli J; Fehér I; Kovács P
Stem Cells; 1994 Sep; 12(5):533-8. PubMed ID: 7804126
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow purging in patients with refractory cancer.
Meagher RC; Stevens DA; Herzig GP; Fay JW; Harden EA; Montes VM; Heye MM; Herzig RH
Prog Clin Biol Res; 1992; 377():281-7. PubMed ID: 1438426
[No Abstract] [Full Text] [Related]
18. Drug-mediated marrow purging: mafosfamide in adult acute leukemia in remission. The experience of the Italian study group.
Rizzoli U; Mangoni L; Carella AM; Aglietta M; Porcellini A; Coleselli P; Angrilli F; Alessandrino EP; Madon E; Locatelli F
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():190-4. PubMed ID: 2653502
[No Abstract] [Full Text] [Related]
19. The cytotoxicity of alkyl-lysophospholipid on clonogenic leukemia cells and on normal bone marrow progenitor cells is highly, but differentially, increased by cryopreservation.
Verdonck LF; Heesbeen EC; van Heugten HG; Staal GE; Rijksen G
Bone Marrow Transplant; 1992 Apr; 9(4):241-5. PubMed ID: 1600412
[TBL] [Abstract][Full Text] [Related]
20. Difference in kinetics of hematopoietic reconstitution between ALL and ANLL after autologous bone marrow transplantation with marrow treated in vitro with mafosfamide (ASTA Z 7557).
Douay L; Laporte JP; Mary JY; Lopez M; Lemonnier MP; Stachowiak J; Benitez O; Deloux J; Najman A; Salmon C
Bone Marrow Transplant; 1987 Jun; 2(1):33-43. PubMed ID: 3332155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
